Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Int J Hematol. 2010 Jul;92(1):204-7. doi: 10.1007/s12185-010-0606-9. Epub 2010 Jun 1.
Severe graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). However, there have been only a few limited therapeutic options for the treatment of GVHD. Here we have reported two cases of the patients with acute steroid-refractory GVHD who underwent allogeneic HSCT. These patients received infusions of third-party clonal mesenchymal stem cells (cMSCs), which were isolated by a subfractionation culturing method (SCM) developed recently by our group, and showed marked improvement of the disease. MSCs represent a new potential therapeutic option in the treatment of steroid-refractory acute GVHD. They showed safety and improved clinical findings of the acute GVHD patients. However, further investigations are needed to understand the accurate mechanisms of MSCs and larger well-designed human clinical trials are necessary to prove further the safety and efficacy of the cMSCs for the treatment of acute GVHD patients.
严重的移植物抗宿主病（GVHD）是异基因造血干细胞移植（HSCT）的致命并发症。然而，对于 GVHD 的治疗，仅有少数有限的治疗选择。在这里，我们报告了两例接受异基因 HSCT 的急性激素耐药性 GVHD 患者的病例。这些患者接受了我们小组最近开发的亚分馏培养方法（SCM）分离的第三方克隆间充质干细胞（cMSC）输注，疾病明显改善。MSC 是治疗激素耐药性急性 GVHD 的一种新的潜在治疗选择。它们显示了安全性，并改善了急性 GVHD 患者的临床发现。然而，需要进一步的研究来了解 MSC 的准确机制，并且需要更大规模的精心设计的人体临床试验来进一步证明 cMSC 治疗急性 GVHD 患者的安全性和疗效。
